Skip to main content
. Author manuscript; available in PMC: 2016 Apr 20.
Published in final edited form as: Cell Rep. 2016 Apr 7;15(3):519–530. doi: 10.1016/j.celrep.2016.03.054

Figure 4. MED12 and MED23 are required to sustain expression of BRD4, MYC, and MYB target gene signatures in AML cells.

Figure 4

(A–B) Fold-change in FPKM for 8,393 expressed genes in AML (defined by FPKM>5 in shRen sample) following 48 h of doxycycline treatment to induce two independent shRNAs targeting Med12 (401 and 5755) or Med23 (678 and 4061) versus shRen.713. Fold change values for each gene are the average value of the independent hairpins targeting the indicated Mediator subunit. The genes are ranked in order of increasing fold change. The numbers in parentheses represent the fold change expression rank of the indicated genes.

(C–D) Gene Set Enrichment Analysis (GSEA) of shMed12 and shMed23 versus shRen RNA-seq using 10,379 gene sets, including all gene sets in the Molecular Signatures Database. Signatures are plotted by their Normalized Enrichment Scores and FDR q-values according to GSEA.

(E–J) Example GSEA plots from the indicated RNA-seq. Normalized Enrichment Scores (NES) and Nominal p-values (Nom p-value), as calculated by GSEA, are provided.

See also Figure S4 and Table S4.